PL361272A1 - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's diseaseInfo
- Publication number
- PL361272A1 PL361272A1 PL36127201A PL36127201A PL361272A1 PL 361272 A1 PL361272 A1 PL 361272A1 PL 36127201 A PL36127201 A PL 36127201A PL 36127201 A PL36127201 A PL 36127201A PL 361272 A1 PL361272 A1 PL 361272A1
- Authority
- PL
- Poland
- Prior art keywords
- galantamine
- alzheimer
- disease
- treatment
- behaviour associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL361272A1 true PL361272A1 (en) | 2004-10-04 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL36127201A PL361272A1 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (en) |
| JP (1) | JP2003528913A (en) |
| KR (1) | KR20020086911A (en) |
| CN (1) | CN1430514A (en) |
| AU (2) | AU6584401A (en) |
| BG (1) | BG107093A (en) |
| BR (1) | BR0109770A (en) |
| CA (1) | CA2310926C (en) |
| CZ (1) | CZ20023543A3 (en) |
| EE (1) | EE200200554A (en) |
| HR (1) | HRP20020778A2 (en) |
| HU (1) | HUP0300566A3 (en) |
| IL (1) | IL152061A0 (en) |
| MX (1) | MXPA02009777A (en) |
| NO (1) | NO20024746L (en) |
| PL (1) | PL361272A1 (en) |
| RU (1) | RU2002129298A (en) |
| SK (1) | SK15422002A3 (en) |
| WO (1) | WO2001074339A2 (en) |
| ZA (1) | ZA200207935B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ATE374030T1 (en) | 2003-07-25 | 2007-10-15 | Hoffmann La Roche | COMBINATION OF A MGLUR2 ANTAGONIST AND AN ACHE INHIBITOR FOR THE TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISEASES |
| DE10338544B4 (en) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccal formulations of galanthamine and their applications |
| WO2009120277A1 (en) | 2008-03-27 | 2009-10-01 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (en) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements |
| CN107847504A (en) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | The galanthamine of amyloid-beta is removed |
| CN117957003A (en) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | Methods of treating neurodegenerative diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (en) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Process for the isolation of galanthamine |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| US7939522B1 (en) | 1998-11-23 | 2011-05-10 | Bonnie M Davis | Dosage formulations for acetylcholinesterase inhibitors |
| OA11740A (en) * | 1998-12-24 | 2005-05-13 | Janssen Pharmaceutica Nv | Controlled release galantamine composition. |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/en not_active Application Discontinuation
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/en unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/en not_active Withdrawn
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/en unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/en active Pending
- 2001-03-28 AU AU6584401A patent/AU6584401A/en active Pending
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/en not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/en not_active Application Discontinuation
- 2001-03-28 PL PL36127201A patent/PL361272A1/en not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/en unknown
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/en unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 IL IL15206101A patent/IL152061A0/en unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/en unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/en unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/en not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02009777A (en) | 2003-03-27 |
| RU2002129298A (en) | 2004-03-27 |
| BR0109770A (en) | 2003-02-04 |
| AU2001265844B2 (en) | 2005-04-14 |
| CA2310926A1 (en) | 2000-10-04 |
| ZA200207935B (en) | 2004-01-30 |
| JP2003528913A (en) | 2003-09-30 |
| EE200200554A (en) | 2004-04-15 |
| CA2310926C (en) | 2002-10-15 |
| HUP0300566A2 (en) | 2003-06-28 |
| CN1430514A (en) | 2003-07-16 |
| CZ20023543A3 (en) | 2003-03-12 |
| EP1272192A2 (en) | 2003-01-08 |
| SK15422002A3 (en) | 2003-04-01 |
| WO2001074339A3 (en) | 2002-09-12 |
| NO20024746L (en) | 2002-11-28 |
| WO2001074339A2 (en) | 2001-10-11 |
| BG107093A (en) | 2003-06-30 |
| NO20024746D0 (en) | 2002-10-02 |
| HUP0300566A3 (en) | 2004-10-28 |
| AU6584401A (en) | 2001-10-15 |
| KR20020086911A (en) | 2002-11-20 |
| IL152061A0 (en) | 2003-05-29 |
| HRP20020778A2 (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153214A0 (en) | Compounds to treat alzheimer's disease | |
| PT2264018E (en) | Thioflavin derivatives for use in the diagnosis of alzheimer's disease | |
| EP1043991A4 (en) | Treatment for alzheimer's disease | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| HUP0103838A3 (en) | Alzheimer's disease secretase | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| SI1303272T1 (en) | Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| EP1007048A4 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
| HUP0301710A3 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| NO20001869D0 (en) | Procedures for the treatment of Alzheimer's disease | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| HUP0300566A3 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| HUP9903213A3 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease | |
| GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
| AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| EP1181550A4 (en) | Methods for the identification of compounds for the treatment of alzheimer's disease | |
| AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2002364885A8 (en) | Alzheimer's disease model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |